Low-level light treatment ameliorates immune thrombocytopenia
Name
Low-level light.pdf
Size
837.06 KB
Format
Adobe PDF
Checksum (MD5)
612ebf5781461b2b27fb0f5d8d9278fe
Author(s)
Yang, Jingke
Zhang, Qi
Li, Peiyu
Dong, Tingting
Wu, Mei X
Date Issued
November 2016
Journal
Scientific Reports
Publisher
Nature Publishing Group
Citation
Yang, Jingke et al. “Low-Level Light Treatment Ameliorates Immune Thrombocytopenia.” Scientific Reports 6.1 (2016): n. pag.
Version
Final published version
Abstract
Immune thrombocytopenia (ITP) is an immune-mediated acquired bleeding disorder characterized by abnormally low platelet counts. We reported here the ability of low-level light treatment (LLLT) to alleviate ITP in mice. The treatment is based on noninvasive whole body illumination 30 min a day for a few consecutive days by near infrared light (830 nm) transmitted by an array of light-emitting diodes (LEDs). LLLT significantly lifted the nadir of platelet counts and restored tail bleeding time when applied to two passive ITP models induced by anti-CD41 antibody. The anti-platelet antibody hindered megakaryocyte differentiation from the progenitors, impaired proplatelet and platelet formation, and induced apoptosis of platelets. These adverse effects of anti-CD41 antibody were all mitigated by LLLT to varying degrees, owing to its ability to enhance mitochondrial biogenesis and activity in megakaryocytes and preserve mitochondrial functions in platelets in the presence of the antibody. The observations argue not only for contribution of mitochondrial stress to the pathology of ITP, but also clinical potentials of LLLT as a safe, simple, and cost-effective modality of ITP.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Creative Commons Attribution 4.0 International License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/srep38238
